A specialty pharmaceutical company which is engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Endo's a fun stock even though their lack of an internal pipeline puts them outside of my developmental biopharma expertise. Over the last couple of years I've watched them grow rapidly through debt-fueled acquisitions. I don't know much about the long-term viability and risks of such a strategy, but Wall Street seems to have liked the approach. Lately, the stock has been off recent highs close to 40. The company has experienced several minor setbacks including manufacturing issues of Voltaren Gel and Opana ER that adversely impacted earnings, as well as a large legal payout to Impax, that has knocked the share price back below 30.
I'm betting that the current retrace is a temporary phenomenon and that Endo stock will resume its upward trajectory once the next quarterly revenues are in line with company guidance. Of course, if Europe implodes between now and then all bets are off in the short term.